Anxiety trial versus medazepam
In patients with generalized anxiety disorder and neurasthenia, Selank produced anxiolytic effects broadly comparable to the benzodiazepine-class comparator medazepam, with additional reported anti-asthenic and psychostimulant effects not seen with medazepam; treatment was associated with normalisation of plasma leu-enkephalin levels that had been reduced at baseline relative to disease severity/duration.
- Study type
- Human trial
- Population
- 62 patients with GAD/neurasthenia (30 Selank, 32 medazepam, active-comparator design)
- Source
- 1 Zozulia et al., 2008
Limitation: Active-comparator design (medazepam), not placebo-controlled, so the finding demonstrates comparability to an existing anxiolytic rather than superiority to no treatment; single trial, single research group, no replication by an independent group has been identified; sample size is modest (n=62).